Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 4
2005 2
2006 9
2007 7
2008 6
2009 4
2010 7
2011 6
2012 7
2013 4
2014 13
2015 13
2016 13
2017 11
2018 17
2019 16
2020 17
2021 15
2022 15
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
Aldred B, Lyles RH, Scott JY, Gromer DJ, Aldredge A, Workowski KA, Wiley Z, Titanji BK, Szabo B, Sheth AN, Rebolledo PA, Nguyen ML, Marconi VC, Kelley CF, Kandiah S, Kalapila A, Jacob JT, Hall B, Colasanti JA, Cartwright EJ, Cantos VD. Aldred B, et al. Among authors: scott jy. JAMA Intern Med. 2024 Mar 1;184(3):275-279. doi: 10.1001/jamainternmed.2023.7696. JAMA Intern Med. 2024. PMID: 38190312
Associations Between HIV and Severe Mpox in an Atlanta Cohort.
Aldred B, Scott JY, Aldredge A, Gromer DJ, Anderson AM, Cartwright EJ, Colasanti JA, Hall B, Jacob JT, Kalapila A, Kandiah S, Kelley CF, Lyles RH, Marconi VC, Nguyen ML, Rebolledo PA, Sheth AN, Szabo B, Titanji BK, Wiley Z, Workowski K, Cantos VD. Aldred B, et al. Among authors: scott jy. J Infect Dis. 2024 Mar 26;229(Supplement_2):S234-S242. doi: 10.1093/infdis/jiad505. J Infect Dis. 2024. PMID: 38001044
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Nilsson AC, Pullman J, Napora P, Luz K, Gupta A, Draghi J, Guzman Romero AK, Aggarwal N, Petrova G, Ianus J, Vijgen L, Scott J, Sinha R, Rusch S, Huntjens D, Bertzos K, Stevens M; ROSE Study Group. Nilsson AC, et al. Among authors: scott j. Clin Microbiol Infect. 2023 Oct;29(10):1320-1327. doi: 10.1016/j.cmi.2023.07.004. Epub 2023 Jul 6. Clin Microbiol Infect. 2023. PMID: 37422079 Clinical Trial.
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
Osborne RH, Nelson LM, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Vandendijck Y, Norcross L, Heijnen E, Ispas G, Comeaux C, Callendret B, Chan EKH, Scott JA. Osborne RH, et al. Among authors: scott ja. J Patient Rep Outcomes. 2023 Jun 1;7(1):51. doi: 10.1186/s41687-023-00593-9. J Patient Rep Outcomes. 2023. PMID: 37261682 Free PMC article.
195 results